UNSPSC 51383705: Bumadizone calcium

This classification denotes a nonsteroidal antiinflammatory drug 4C19H21N2O3.2Ca.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7PSH384AJD, chemically known as calcium 2-(1,2-diphenylhydrazinocarbonyl)hexanoate hemihydrate, but more generally known as bumadizone calcium, which bears US NIH Compound Identifier 36833. European Medicines Agency schedules Bumadizone calcium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00896MIG.

UNSPSC 51383705 Bumadizone calcium is a Commodity code that nominally identifies a specific pharmaceutical ingredient, yet recent state and local procurement activity under this code does not reflect purchases of bumadizone calcium itself. Instead, the code tags solicitations for naloxone, safe drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products. State and local buyers soliciting under this code include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. The work being solicited ranges from routine pharmaceutical supply agreements with quarterly delivery schedules to exploratory requests for information about innovative pharmacy benefit management models and direct contracting strategies between state agencies and manufacturers outside traditional pharmacy benefit manager and wholesaler channels.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, requiring quarterly deliveries to the Seminole County Community Health Building and E-Verify compliance. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information about direct contracting arrangements and value-based agreements outside traditional PBM structures. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 with a response deadline of March 26, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products through authorized wholesalers including AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson, with awarded vendors effective July 1, 2026 and price competitiveness weighted at 75 percent of the evaluation.